Cornerstone Investments
Contributor since: 2016
Articles
Sundial Growers: Finding Ways To Spend That $1.1B Cash
Hydrofarm: Richly Valued Despite Low Margins
Green Thumb: Putting Competitors To Shame Again
Trulieve: A Screaming Buy After The Harvest Acquisition
Valens Company: Time To Take Profits After 100% Rally
Cronos: The Most Confusing Cannabis Stock
OrganiGram: The Hype Is Over
HEXO: The Winning Streak In Canada Continues
Tilray: Mania Ended But Still Frothy
Curaleaf: 2021 Could Bring New Growth Challenges
Canopy Growth: Supreme Deal Raised More Questions
Cresco Labs: Revving Up The M&A Machine Again
Harvest Health: Levered Balance Sheet Leads To High Beta
Verano: Latest Addition To The Top U.S. Cannabis MSOs
Aphria: Time For A Break After 150% Rally This Year
Ayr Wellness: Ambitious 2020 Outlook Built On Acquisitions
Columbia Care: Low Profitability Overshadows M&A Strategy
Trulieve: This Top Cannabis Stock Is On Sale
Greenlane: Merging With KushCo Makes A Lot Of Sense
Green Thumb: Capping Off An Extraordinary 2020
Canopy Growth: Stay Away Due To Weak Fundamentals
Aurora Cannabis: The Dilution Nightmare Lives On
OrganiGram: Don't Get Too Excited After The BAT Investment
High Tide: Leading Cannabis Retailer With Upside In 2021
Vireo Health: The Achilles' Heel Of Multi-State Operators
Fire & Flower: Nasdaq-Bound Cannabis Retailer With Deep-Pocketed Backer
4Front Ventures: OK Assets With Top-Of-The-Line Valuation
MedMen: A Turnaround Looks Increasingly Unlikely
Weedmaps: A Rare Combination Of Cannabis, Tech And SPAC
Cansortium: One Of Few Remaining Florida Cannabis Gems
The Green Organic Dutchman: Hitting The Reset Button
TerrAscend: Strong Q4 Results Not Enough To Justify Valuation
Trulieve: Bullish Thesis Unchanged Despite Reefer Madness
Jushi: Building An MSO From The Ground Up
Auxly: 2020 Was A Milestone, But It Came At Great Costs
Valens Company: Arming The Rebels In Cannabis 2.0
Hydrofarm: Hydroponics Pure-Play Riding High On Cannabis
Supreme Cannabis: Long Road Ahead For A Turnaround
MediPharm: We Were Wrong
Aleafia Health: Slow Start, But 2021 Could Prove Pivotal